By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seqirus, A CSL Company 

One Health Plaza
East Village Promenade

310/4th floor
East Hanover  New Jersey  07936-1080  U.S.A.
Phone: 1-919-577-5000 Fax: n/a


In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.

With research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.

Seqirus has a corporate office in Maidenhead, United Kingdom.




All Products

Key Statistics

Ownership: Private

Web Site: Seqirus

Company News
Seqirus and Zambon Release: Companies Enter Into A Partnership For Parkinson’s Disease Product In Australia And New Zealand 1/10/2017 10:58:00 AM
Seqirus Presents Analysis Reinforcing The Safety And Immunogenicity Profiles Of Its MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine In Adults 65 Years And Older 8/29/2016 11:03:17 AM
PaxVax, Inc. Inks Swiss Marketing And Distribution Agreement With Seqirus For Influenza Vaccines 8/29/2016 10:24:51 AM
Seqirus To Highlight New Data In Seasonal Influenza Prevention At Options IX For The Control Of Influenza Conference 8/25/2016 10:27:02 AM
Seqirus Presents Integrated Analyses For Trivalent Adjuvanted Seasonal Influenza Vaccine For Young Children 8/24/2016 10:32:15 AM
Seqirus Receives FDA Approval For FLUCELVAX QUADRIVALENT (Influenza Vaccine) For People Four Years Of Age And Older 5/24/2016 6:21:51 AM